Key Highlights

  • Alpha Teknova (NASDAQ:TKNO) reported third-quarter Revenue of USD 12.7 million, up 22% from USD 10.5 million, and described it as a second consecutive record quarter.
  • Clinical Solutions revenue rose 86% to USD 3.2 million, while Lab Essentials rose 9% to USD 9.0 million, and gross Margin widened to 38.0% from 30.7%.
  • Net loss narrowed to USD 3.5 million, or USD 0.06 per diluted share, from USD 4.3 million, or USD 0.08, and Adjusted EBITDA improved to negative USD 1.0 million from negative USD 1.6 million.
  • On October 22, 2026, the company closed a public offering of 9,200,000 shares at USD 5.00, for gross proceeds of USD 46.0 million and net proceeds of about USD 42.9 million.

Clinical Solutions Drives a Second Record Quarter

Alpha Teknova (NASDAQ:TKNO) reported third-quarter 2026 results on November 4, 2026. The Hollister, California company makes reagents such as agar plates, culture media and buffers for drug discovery, vaccines and molecular diagnostics. Revenue was USD 12.7 million. Clinical Solutions revenue was up 86%, from USD 1.7 million, and Lab Essentials was up 9% from USD 8.3 million, with the Other category adding USD 0.5 million. Nine-month Clinical Solutions revenue rose to USD 7.7 million from USD 4.9 million. The chief executive said purchases of custom products by small and mid-sized biotech customers and their contract manufacturers may signal an early improvement in biotech funding, a view the company stated as belief rather than a measured result.

Gross Margin Gains, Wider Spending and a Smaller Loss

Gross profit was USD 4.8 million, a margin of 38.0%, helped by higher revenue and lower Fixed Cost absorption into cost of goods sold. Operating expenses rose to USD 8.0 million from USD 7.2 million, driven by sales and Marketing headcount and slightly higher general and administrative costs, partly offset by lower stock-based compensation. Net loss narrowed to USD 3.5 million. Cash used in Operating Activities was USD 1.3 million, and Free Cash Outflow was USD 1.4 million against USD 2.4 million. Over nine months, revenue rose to USD 36.0 million from USD 30.5 million, and Gross Profit reached USD 13.5 million against USD 10.2 million. The release names a conference call on November 4, 2026 to discuss results and outlook. Alpha Teknova (NASDAQ:TKNO) also launched its Fill-Tek Dispensing System in the period.

The Offering, Raised Guidance and Dilution Mechanics

Total cash and short-term investments were USD 16.6 million at quarter-end, against borrowings of USD 13.2 million, before the October offering. Selling 9,200,000 new shares raises cash but increases the share count, which spreads future Earnings across more shares. The company now expects 2026 revenue of USD 46 million to USD 48 million, raised from its prior outlook, and still expects Free Cash Outflow below USD 8 million. Management will present at investor conferences on November 17 and 18, 2026. The company remains loss-making, so future funding needs are a risk. Selling and marketing expense rose to USD 2.3 million from USD 1.7 million, and general and administrative expense was USD 4.8 million.

Where Things Stand

Growth looks real in the quarter, but sustaining it depends on biotech Demand and on a company that is still burning cash. Alpha Teknova (NASDAQ:TKNO) raised revenue guidance and cut its loss, and the October offering gives it more room than the USD 16.6 million held at quarter-end. The cost is a larger share count. Next markers are the November 17 and 18 investor conferences, fourth-quarter revenue against the raised range and the Free Cash Outflow target.